http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 06 May 2025 16:38:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/BetterLife+Announces+Debt+Settlements/24750822.html <p align="justify">VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=tcbSOusV72hKK4B7mvxwKrfzQlethbRVZdzjZpvZXqXIu9-KFjqUT_UZUrxxJmaqcwFTr9X-_JBkNN6eYvmfE9a3aX9ywPfoMDJP-Sc23Vm6yccvH0sLIeCSwGKvGZsLfdApEPoy-7T2Avsh0iCdWA==" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=yUWXbno2EADQ-NNDFD_aOGtH0ziPDF2zkps-lCi_n6fdJYtteD6vJok_SmiMS00i7DiM4BWenhltW21QLeurh4Xt8sA6iAzW_gfK9-ZGTtM=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=sQfo8bkfAPtgKCqx1QvOJTRZPT5uQsK-48cxKfuo3S6JsrCFoAnLQWQBF6JwZVRw-vn4bz9B4JIuFl0Xf71Dn_k5IcrkFXUNRVX6ok5a5Wswi5fOCO8e9uIjlWSaIsy6" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic neuroplastogen in the treatment of psychiatric and neurological disorders,   announces that it has issued 14,999,303 common shares pursuant to the settlement of accounts payable and amounts due to directors and officers totaling $1,499,930. The common shares issued will be subject to a four month hold period pursuant to applicable Canadian http://www.streetinsider.com/Press+Releases/BetterLife+Announces+Debt+Settlements/24750822.html Tue, 06 May 2025 16:38:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Press+Releases/BetterLife+Announces+Debt+Settlements/24750822.html <p align="justify">VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=tcbSOusV72hKK4B7mvxwKrfzQlethbRVZdzjZpvZXqXIu9-KFjqUT_UZUrxxJmaqcwFTr9X-_JBkNN6eYvmfE9a3aX9ywPfoMDJP-Sc23Vm6yccvH0sLIeCSwGKvGZsLfdApEPoy-7T2Avsh0iCdWA==" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=yUWXbno2EADQ-NNDFD_aOGtH0ziPDF2zkps-lCi_n6fdJYtteD6vJok_SmiMS00i7DiM4BWenhltW21QLeurh4Xt8sA6iAzW_gfK9-ZGTtM=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=sQfo8bkfAPtgKCqx1QvOJTRZPT5uQsK-48cxKfuo3S6JsrCFoAnLQWQBF6JwZVRw-vn4bz9B4JIuFl0Xf71Dn_k5IcrkFXUNRVX6ok5a5Wswi5fOCO8e9uIjlWSaIsy6" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic neuroplastogen in the treatment of psychiatric and neurological disorders,   announces that it has issued 14,999,303 common shares pursuant to the settlement of accounts payable and amounts due to directors and officers totaling $1,499,930. The common shares issued will be subject to a four month hold period pursuant to applicable Canadian http://www.streetinsider.com/Press+Releases/BetterLife+Announces+Debt+Settlements/24750822.html Tue, 06 May 2025 16:38:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Press+Releases/BetterLife+Announces+Debt+Settlements/24750822.html <p align="justify">VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=tcbSOusV72hKK4B7mvxwKrfzQlethbRVZdzjZpvZXqXIu9-KFjqUT_UZUrxxJmaqcwFTr9X-_JBkNN6eYvmfE9a3aX9ywPfoMDJP-Sc23Vm6yccvH0sLIeCSwGKvGZsLfdApEPoy-7T2Avsh0iCdWA==" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=yUWXbno2EADQ-NNDFD_aOGtH0ziPDF2zkps-lCi_n6fdJYtteD6vJok_SmiMS00i7DiM4BWenhltW21QLeurh4Xt8sA6iAzW_gfK9-ZGTtM=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=sQfo8bkfAPtgKCqx1QvOJTRZPT5uQsK-48cxKfuo3S6JsrCFoAnLQWQBF6JwZVRw-vn4bz9B4JIuFl0Xf71Dn_k5IcrkFXUNRVX6ok5a5Wswi5fOCO8e9uIjlWSaIsy6" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic neuroplastogen in the treatment of psychiatric and neurological disorders,   announces that it has issued 14,999,303 common shares pursuant to the settlement of accounts payable and amounts due to directors and officers totaling $1,499,930. The common shares issued will be subject to a four month hold period pursuant to applicable Canadian http://www.streetinsider.com/Press+Releases/BetterLife+Announces+Debt+Settlements/24750822.html Tue, 06 May 2025 16:38:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Press+Releases/BetterLife+Announces+Debt+Settlements/24750822.html <p align="justify">VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=tcbSOusV72hKK4B7mvxwKrfzQlethbRVZdzjZpvZXqXIu9-KFjqUT_UZUrxxJmaqcwFTr9X-_JBkNN6eYvmfE9a3aX9ywPfoMDJP-Sc23Vm6yccvH0sLIeCSwGKvGZsLfdApEPoy-7T2Avsh0iCdWA==" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=yUWXbno2EADQ-NNDFD_aOGtH0ziPDF2zkps-lCi_n6fdJYtteD6vJok_SmiMS00i7DiM4BWenhltW21QLeurh4Xt8sA6iAzW_gfK9-ZGTtM=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=sQfo8bkfAPtgKCqx1QvOJTRZPT5uQsK-48cxKfuo3S6JsrCFoAnLQWQBF6JwZVRw-vn4bz9B4JIuFl0Xf71Dn_k5IcrkFXUNRVX6ok5a5Wswi5fOCO8e9uIjlWSaIsy6" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic neuroplastogen in the treatment of psychiatric and neurological disorders,   announces that it has issued 14,999,303 common shares pursuant to the settlement of accounts payable and amounts due to directors and officers totaling $1,499,930. The common shares issued will be subject to a four month hold period pursuant to applicable Canadian http://www.streetinsider.com/Press+Releases/BetterLife+Announces+Debt+Settlements/24750822.html Tue, 06 May 2025 16:38:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Globe+Newswire/BetterLife+Announces+Debt+Settlements/24750822.html <p align="justify">VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=tcbSOusV72hKK4B7mvxwKrfzQlethbRVZdzjZpvZXqXIu9-KFjqUT_UZUrxxJmaqcwFTr9X-_JBkNN6eYvmfE9a3aX9ywPfoMDJP-Sc23Vm6yccvH0sLIeCSwGKvGZsLfdApEPoy-7T2Avsh0iCdWA==" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=yUWXbno2EADQ-NNDFD_aOGtH0ziPDF2zkps-lCi_n6fdJYtteD6vJok_SmiMS00i7DiM4BWenhltW21QLeurh4Xt8sA6iAzW_gfK9-ZGTtM=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=sQfo8bkfAPtgKCqx1QvOJTRZPT5uQsK-48cxKfuo3S6JsrCFoAnLQWQBF6JwZVRw-vn4bz9B4JIuFl0Xf71Dn_k5IcrkFXUNRVX6ok5a5Wswi5fOCO8e9uIjlWSaIsy6" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic neuroplastogen in the treatment of psychiatric and neurological disorders,   announces that it has issued 14,999,303 common shares pursuant to the settlement of accounts payable and amounts due to directors and officers totaling $1,499,930. The common shares issued will be subject to a four month hold period pursuant to applicable Canadian http://www.streetinsider.com/Globe+Newswire/BetterLife+Announces+Debt+Settlements/24750822.html Tue, 06 May 2025 16:38:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Globe+Newswire/BetterLife+Announces+Debt+Settlements/24750822.html <p align="justify">VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=tcbSOusV72hKK4B7mvxwKrfzQlethbRVZdzjZpvZXqXIu9-KFjqUT_UZUrxxJmaqcwFTr9X-_JBkNN6eYvmfE9a3aX9ywPfoMDJP-Sc23Vm6yccvH0sLIeCSwGKvGZsLfdApEPoy-7T2Avsh0iCdWA==" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=yUWXbno2EADQ-NNDFD_aOGtH0ziPDF2zkps-lCi_n6fdJYtteD6vJok_SmiMS00i7DiM4BWenhltW21QLeurh4Xt8sA6iAzW_gfK9-ZGTtM=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=sQfo8bkfAPtgKCqx1QvOJTRZPT5uQsK-48cxKfuo3S6JsrCFoAnLQWQBF6JwZVRw-vn4bz9B4JIuFl0Xf71Dn_k5IcrkFXUNRVX6ok5a5Wswi5fOCO8e9uIjlWSaIsy6" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic neuroplastogen in the treatment of psychiatric and neurological disorders,   announces that it has issued 14,999,303 common shares pursuant to the settlement of accounts payable and amounts due to directors and officers totaling $1,499,930. The common shares issued will be subject to a four month hold period pursuant to applicable Canadian http://www.streetinsider.com/Globe+Newswire/BetterLife+Announces+Debt+Settlements/24750822.html Tue, 06 May 2025 16:38:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Globe+Newswire/BetterLife+Announces+Debt+Settlements/24750822.html <p align="justify">VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=tcbSOusV72hKK4B7mvxwKrfzQlethbRVZdzjZpvZXqXIu9-KFjqUT_UZUrxxJmaqcwFTr9X-_JBkNN6eYvmfE9a3aX9ywPfoMDJP-Sc23Vm6yccvH0sLIeCSwGKvGZsLfdApEPoy-7T2Avsh0iCdWA==" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=yUWXbno2EADQ-NNDFD_aOGtH0ziPDF2zkps-lCi_n6fdJYtteD6vJok_SmiMS00i7DiM4BWenhltW21QLeurh4Xt8sA6iAzW_gfK9-ZGTtM=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=sQfo8bkfAPtgKCqx1QvOJTRZPT5uQsK-48cxKfuo3S6JsrCFoAnLQWQBF6JwZVRw-vn4bz9B4JIuFl0Xf71Dn_k5IcrkFXUNRVX6ok5a5Wswi5fOCO8e9uIjlWSaIsy6" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic neuroplastogen in the treatment of psychiatric and neurological disorders,   announces that it has issued 14,999,303 common shares pursuant to the settlement of accounts payable and amounts due to directors and officers totaling $1,499,930. The common shares issued will be subject to a four month hold period pursuant to applicable Canadian http://www.streetinsider.com/Globe+Newswire/BetterLife+Announces+Debt+Settlements/24750822.html Tue, 06 May 2025 16:38:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Globe+Newswire/BetterLife+Announces+Debt+Settlements/24750822.html <p align="justify">VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=tcbSOusV72hKK4B7mvxwKrfzQlethbRVZdzjZpvZXqXIu9-KFjqUT_UZUrxxJmaqcwFTr9X-_JBkNN6eYvmfE9a3aX9ywPfoMDJP-Sc23Vm6yccvH0sLIeCSwGKvGZsLfdApEPoy-7T2Avsh0iCdWA==" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=yUWXbno2EADQ-NNDFD_aOGtH0ziPDF2zkps-lCi_n6fdJYtteD6vJok_SmiMS00i7DiM4BWenhltW21QLeurh4Xt8sA6iAzW_gfK9-ZGTtM=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=sQfo8bkfAPtgKCqx1QvOJTRZPT5uQsK-48cxKfuo3S6JsrCFoAnLQWQBF6JwZVRw-vn4bz9B4JIuFl0Xf71Dn_k5IcrkFXUNRVX6ok5a5Wswi5fOCO8e9uIjlWSaIsy6" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic neuroplastogen in the treatment of psychiatric and neurological disorders,   announces that it has issued 14,999,303 common shares pursuant to the settlement of accounts payable and amounts due to directors and officers totaling $1,499,930. The common shares issued will be subject to a four month hold period pursuant to applicable Canadian http://www.streetinsider.com/Globe+Newswire/BetterLife+Announces+Debt+Settlements/24750822.html Tue, 06 May 2025 16:38:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Press+Releases/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html <p>VANCOUVER, British Columbia, April 03, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=0f0_bQCbBR9WC7aPx7vXsG5XFNCZyIaBzXBBwvBA4F46jAiXb4k94SnDgXp2CFirrOCM_cFja1Z--ZTNMG3XH4CZYFtrLnPaTb6sLbJ-X8CkbJSgNwPUFbJzRSut9xdb" rel="nofollow" target="_blank">CSE: BETR</a> / <a target="_blank" href="https://www.globenewswire.com/Tracker?data=aKHREkPOrs1xvPIIu7foE3o9Qh7_0pcKH1odIc-PcswvxEtwOyvbxDdYg3maCaajjvRbMD5NmUfV2A3YLnheUSOFaDjA0mVrC_5evsQhjzedi6Y2W0BO-QlaS3EXIA2X" rel="nofollow" target="_blank">OTCQB : BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=L5gBT5idHzGzqYVjX03Aw8vMbRS39YTcIhtjvccg69u6wlKrXV6KoJpbILAs0Q2P1K_iI_cXqe9tnHxqCffeXkuQ9l3Otn_6Tya9XI4LknFlNH5KMIxudejm9o8snU1f" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company, has announced that it has appointed André Beaudry as Corporate Advisor. Mr. Beaudry has over 30 years of experience in the areas of fundraising, government relations, national and international program management, as well as governance.</p> <p align="justify">Mr. Beaudry has led teams in Canada, China, England, India and the Philippines, and collaborated with industry, education, http://www.streetinsider.com/Press+Releases/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html Thu, 03 Apr 2025 08:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Press+Releases/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html <p>VANCOUVER, British Columbia, April 03, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=0f0_bQCbBR9WC7aPx7vXsG5XFNCZyIaBzXBBwvBA4F46jAiXb4k94SnDgXp2CFirrOCM_cFja1Z--ZTNMG3XH4CZYFtrLnPaTb6sLbJ-X8CkbJSgNwPUFbJzRSut9xdb" rel="nofollow" target="_blank">CSE: BETR</a> / <a target="_blank" href="https://www.globenewswire.com/Tracker?data=aKHREkPOrs1xvPIIu7foE3o9Qh7_0pcKH1odIc-PcswvxEtwOyvbxDdYg3maCaajjvRbMD5NmUfV2A3YLnheUSOFaDjA0mVrC_5evsQhjzedi6Y2W0BO-QlaS3EXIA2X" rel="nofollow" target="_blank">OTCQB : BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=L5gBT5idHzGzqYVjX03Aw8vMbRS39YTcIhtjvccg69u6wlKrXV6KoJpbILAs0Q2P1K_iI_cXqe9tnHxqCffeXkuQ9l3Otn_6Tya9XI4LknFlNH5KMIxudejm9o8snU1f" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company, has announced that it has appointed André Beaudry as Corporate Advisor. Mr. Beaudry has over 30 years of experience in the areas of fundraising, government relations, national and international program management, as well as governance.</p> <p align="justify">Mr. Beaudry has led teams in Canada, China, England, India and the Philippines, and collaborated with industry, education, http://www.streetinsider.com/Press+Releases/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html Thu, 03 Apr 2025 08:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Press+Releases/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html <p>VANCOUVER, British Columbia, April 03, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=0f0_bQCbBR9WC7aPx7vXsG5XFNCZyIaBzXBBwvBA4F46jAiXb4k94SnDgXp2CFirrOCM_cFja1Z--ZTNMG3XH4CZYFtrLnPaTb6sLbJ-X8CkbJSgNwPUFbJzRSut9xdb" rel="nofollow" target="_blank">CSE: BETR</a> / <a target="_blank" href="https://www.globenewswire.com/Tracker?data=aKHREkPOrs1xvPIIu7foE3o9Qh7_0pcKH1odIc-PcswvxEtwOyvbxDdYg3maCaajjvRbMD5NmUfV2A3YLnheUSOFaDjA0mVrC_5evsQhjzedi6Y2W0BO-QlaS3EXIA2X" rel="nofollow" target="_blank">OTCQB : BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=L5gBT5idHzGzqYVjX03Aw8vMbRS39YTcIhtjvccg69u6wlKrXV6KoJpbILAs0Q2P1K_iI_cXqe9tnHxqCffeXkuQ9l3Otn_6Tya9XI4LknFlNH5KMIxudejm9o8snU1f" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company, has announced that it has appointed André Beaudry as Corporate Advisor. Mr. Beaudry has over 30 years of experience in the areas of fundraising, government relations, national and international program management, as well as governance.</p> <p align="justify">Mr. Beaudry has led teams in Canada, China, England, India and the Philippines, and collaborated with industry, education, http://www.streetinsider.com/Press+Releases/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html Thu, 03 Apr 2025 08:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Press+Releases/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html <p>VANCOUVER, British Columbia, April 03, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=0f0_bQCbBR9WC7aPx7vXsG5XFNCZyIaBzXBBwvBA4F46jAiXb4k94SnDgXp2CFirrOCM_cFja1Z--ZTNMG3XH4CZYFtrLnPaTb6sLbJ-X8CkbJSgNwPUFbJzRSut9xdb" rel="nofollow" target="_blank">CSE: BETR</a> / <a target="_blank" href="https://www.globenewswire.com/Tracker?data=aKHREkPOrs1xvPIIu7foE3o9Qh7_0pcKH1odIc-PcswvxEtwOyvbxDdYg3maCaajjvRbMD5NmUfV2A3YLnheUSOFaDjA0mVrC_5evsQhjzedi6Y2W0BO-QlaS3EXIA2X" rel="nofollow" target="_blank">OTCQB : BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=L5gBT5idHzGzqYVjX03Aw8vMbRS39YTcIhtjvccg69u6wlKrXV6KoJpbILAs0Q2P1K_iI_cXqe9tnHxqCffeXkuQ9l3Otn_6Tya9XI4LknFlNH5KMIxudejm9o8snU1f" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company, has announced that it has appointed André Beaudry as Corporate Advisor. Mr. Beaudry has over 30 years of experience in the areas of fundraising, government relations, national and international program management, as well as governance.</p> <p align="justify">Mr. Beaudry has led teams in Canada, China, England, India and the Philippines, and collaborated with industry, education, http://www.streetinsider.com/Press+Releases/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html Thu, 03 Apr 2025 08:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Globe+Newswire/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html <p>VANCOUVER, British Columbia, April 03, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=0f0_bQCbBR9WC7aPx7vXsG5XFNCZyIaBzXBBwvBA4F46jAiXb4k94SnDgXp2CFirrOCM_cFja1Z--ZTNMG3XH4CZYFtrLnPaTb6sLbJ-X8CkbJSgNwPUFbJzRSut9xdb" rel="nofollow" target="_blank">CSE: BETR</a> / <a target="_blank" href="https://www.globenewswire.com/Tracker?data=aKHREkPOrs1xvPIIu7foE3o9Qh7_0pcKH1odIc-PcswvxEtwOyvbxDdYg3maCaajjvRbMD5NmUfV2A3YLnheUSOFaDjA0mVrC_5evsQhjzedi6Y2W0BO-QlaS3EXIA2X" rel="nofollow" target="_blank">OTCQB : BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=L5gBT5idHzGzqYVjX03Aw8vMbRS39YTcIhtjvccg69u6wlKrXV6KoJpbILAs0Q2P1K_iI_cXqe9tnHxqCffeXkuQ9l3Otn_6Tya9XI4LknFlNH5KMIxudejm9o8snU1f" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company, has announced that it has appointed André Beaudry as Corporate Advisor. Mr. Beaudry has over 30 years of experience in the areas of fundraising, government relations, national and international program management, as well as governance.</p> <p align="justify">Mr. Beaudry has led teams in Canada, China, England, India and the Philippines, and collaborated with industry, education, http://www.streetinsider.com/Globe+Newswire/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html Thu, 03 Apr 2025 08:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Globe+Newswire/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html <p>VANCOUVER, British Columbia, April 03, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=0f0_bQCbBR9WC7aPx7vXsG5XFNCZyIaBzXBBwvBA4F46jAiXb4k94SnDgXp2CFirrOCM_cFja1Z--ZTNMG3XH4CZYFtrLnPaTb6sLbJ-X8CkbJSgNwPUFbJzRSut9xdb" rel="nofollow" target="_blank">CSE: BETR</a> / <a target="_blank" href="https://www.globenewswire.com/Tracker?data=aKHREkPOrs1xvPIIu7foE3o9Qh7_0pcKH1odIc-PcswvxEtwOyvbxDdYg3maCaajjvRbMD5NmUfV2A3YLnheUSOFaDjA0mVrC_5evsQhjzedi6Y2W0BO-QlaS3EXIA2X" rel="nofollow" target="_blank">OTCQB : BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=L5gBT5idHzGzqYVjX03Aw8vMbRS39YTcIhtjvccg69u6wlKrXV6KoJpbILAs0Q2P1K_iI_cXqe9tnHxqCffeXkuQ9l3Otn_6Tya9XI4LknFlNH5KMIxudejm9o8snU1f" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company, has announced that it has appointed André Beaudry as Corporate Advisor. Mr. Beaudry has over 30 years of experience in the areas of fundraising, government relations, national and international program management, as well as governance.</p> <p align="justify">Mr. Beaudry has led teams in Canada, China, England, India and the Philippines, and collaborated with industry, education, http://www.streetinsider.com/Globe+Newswire/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html Thu, 03 Apr 2025 08:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Globe+Newswire/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html <p>VANCOUVER, British Columbia, April 03, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=0f0_bQCbBR9WC7aPx7vXsG5XFNCZyIaBzXBBwvBA4F46jAiXb4k94SnDgXp2CFirrOCM_cFja1Z--ZTNMG3XH4CZYFtrLnPaTb6sLbJ-X8CkbJSgNwPUFbJzRSut9xdb" rel="nofollow" target="_blank">CSE: BETR</a> / <a target="_blank" href="https://www.globenewswire.com/Tracker?data=aKHREkPOrs1xvPIIu7foE3o9Qh7_0pcKH1odIc-PcswvxEtwOyvbxDdYg3maCaajjvRbMD5NmUfV2A3YLnheUSOFaDjA0mVrC_5evsQhjzedi6Y2W0BO-QlaS3EXIA2X" rel="nofollow" target="_blank">OTCQB : BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=L5gBT5idHzGzqYVjX03Aw8vMbRS39YTcIhtjvccg69u6wlKrXV6KoJpbILAs0Q2P1K_iI_cXqe9tnHxqCffeXkuQ9l3Otn_6Tya9XI4LknFlNH5KMIxudejm9o8snU1f" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company, has announced that it has appointed André Beaudry as Corporate Advisor. Mr. Beaudry has over 30 years of experience in the areas of fundraising, government relations, national and international program management, as well as governance.</p> <p align="justify">Mr. Beaudry has led teams in Canada, China, England, India and the Philippines, and collaborated with industry, education, http://www.streetinsider.com/Globe+Newswire/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html Thu, 03 Apr 2025 08:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Globe+Newswire/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html <p>VANCOUVER, British Columbia, April 03, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=0f0_bQCbBR9WC7aPx7vXsG5XFNCZyIaBzXBBwvBA4F46jAiXb4k94SnDgXp2CFirrOCM_cFja1Z--ZTNMG3XH4CZYFtrLnPaTb6sLbJ-X8CkbJSgNwPUFbJzRSut9xdb" rel="nofollow" target="_blank">CSE: BETR</a> / <a target="_blank" href="https://www.globenewswire.com/Tracker?data=aKHREkPOrs1xvPIIu7foE3o9Qh7_0pcKH1odIc-PcswvxEtwOyvbxDdYg3maCaajjvRbMD5NmUfV2A3YLnheUSOFaDjA0mVrC_5evsQhjzedi6Y2W0BO-QlaS3EXIA2X" rel="nofollow" target="_blank">OTCQB : BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=L5gBT5idHzGzqYVjX03Aw8vMbRS39YTcIhtjvccg69u6wlKrXV6KoJpbILAs0Q2P1K_iI_cXqe9tnHxqCffeXkuQ9l3Otn_6Tya9XI4LknFlNH5KMIxudejm9o8snU1f" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company, has announced that it has appointed André Beaudry as Corporate Advisor. Mr. Beaudry has over 30 years of experience in the areas of fundraising, government relations, national and international program management, as well as governance.</p> <p align="justify">Mr. Beaudry has led teams in Canada, China, England, India and the Philippines, and collaborated with industry, education, http://www.streetinsider.com/Globe+Newswire/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html Thu, 03 Apr 2025 08:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Press+Releases/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html <p align="justify">VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- As a result of a review by the British Columbia Securities Commission, BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pvkcJkvvtpynv9wu8j0ZVeV5fBPK3L0voY2mW9JAMeEfacbVS7PB_18STvUMOcu7znklduQKexKWoawI8WH2SRezVUfrzMSxlrXv6CKIdIb919_4gZDFMIaN9Ba8bTY7" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Knpg4KGB_ZvotlFKdqE3VVqEiZ7Izfw2zv6Nxc5pMnUegF-_v6O5fGaBiPTcQEjmfW7bF-nUsM_4TWeaNa3Z9MqBykb-WKZinsZR11U2BW0=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=c5DB9103egOEZr4RJB67HIK7ENijMcYuYSNHXiJX9nc14NORfOdErGTOKX9UfR1ErB7FO5xk2wR1zFLqtouRixctTaMBYEWmwy8Bx5gWGNC8n8iGUi6YLSOTHKeBZfuc" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), is issuing the following press release to clarify disclosures in its past Management Information Circulars (“MIC”) as it relates to beneficial ownership by its Chief Executive Officer, Dr. Ahmad Doroudian:<br/></p> <table http://www.streetinsider.com/Press+Releases/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html Tue, 16 Jul 2024 18:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Press+Releases/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html <p align="justify">VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- As a result of a review by the British Columbia Securities Commission, BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pvkcJkvvtpynv9wu8j0ZVeV5fBPK3L0voY2mW9JAMeEfacbVS7PB_18STvUMOcu7znklduQKexKWoawI8WH2SRezVUfrzMSxlrXv6CKIdIb919_4gZDFMIaN9Ba8bTY7" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Knpg4KGB_ZvotlFKdqE3VVqEiZ7Izfw2zv6Nxc5pMnUegF-_v6O5fGaBiPTcQEjmfW7bF-nUsM_4TWeaNa3Z9MqBykb-WKZinsZR11U2BW0=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=c5DB9103egOEZr4RJB67HIK7ENijMcYuYSNHXiJX9nc14NORfOdErGTOKX9UfR1ErB7FO5xk2wR1zFLqtouRixctTaMBYEWmwy8Bx5gWGNC8n8iGUi6YLSOTHKeBZfuc" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), is issuing the following press release to clarify disclosures in its past Management Information Circulars (“MIC”) as it relates to beneficial ownership by its Chief Executive Officer, Dr. Ahmad Doroudian:<br/></p> <table http://www.streetinsider.com/Press+Releases/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html Tue, 16 Jul 2024 18:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Press+Releases/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html <p align="justify">VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- As a result of a review by the British Columbia Securities Commission, BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pvkcJkvvtpynv9wu8j0ZVeV5fBPK3L0voY2mW9JAMeEfacbVS7PB_18STvUMOcu7znklduQKexKWoawI8WH2SRezVUfrzMSxlrXv6CKIdIb919_4gZDFMIaN9Ba8bTY7" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Knpg4KGB_ZvotlFKdqE3VVqEiZ7Izfw2zv6Nxc5pMnUegF-_v6O5fGaBiPTcQEjmfW7bF-nUsM_4TWeaNa3Z9MqBykb-WKZinsZR11U2BW0=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=c5DB9103egOEZr4RJB67HIK7ENijMcYuYSNHXiJX9nc14NORfOdErGTOKX9UfR1ErB7FO5xk2wR1zFLqtouRixctTaMBYEWmwy8Bx5gWGNC8n8iGUi6YLSOTHKeBZfuc" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), is issuing the following press release to clarify disclosures in its past Management Information Circulars (“MIC”) as it relates to beneficial ownership by its Chief Executive Officer, Dr. Ahmad Doroudian:<br/></p> <table http://www.streetinsider.com/Press+Releases/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html Tue, 16 Jul 2024 18:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Press+Releases/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html <p align="justify">VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- As a result of a review by the British Columbia Securities Commission, BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pvkcJkvvtpynv9wu8j0ZVeV5fBPK3L0voY2mW9JAMeEfacbVS7PB_18STvUMOcu7znklduQKexKWoawI8WH2SRezVUfrzMSxlrXv6CKIdIb919_4gZDFMIaN9Ba8bTY7" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Knpg4KGB_ZvotlFKdqE3VVqEiZ7Izfw2zv6Nxc5pMnUegF-_v6O5fGaBiPTcQEjmfW7bF-nUsM_4TWeaNa3Z9MqBykb-WKZinsZR11U2BW0=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=c5DB9103egOEZr4RJB67HIK7ENijMcYuYSNHXiJX9nc14NORfOdErGTOKX9UfR1ErB7FO5xk2wR1zFLqtouRixctTaMBYEWmwy8Bx5gWGNC8n8iGUi6YLSOTHKeBZfuc" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), is issuing the following press release to clarify disclosures in its past Management Information Circulars (“MIC”) as it relates to beneficial ownership by its Chief Executive Officer, Dr. Ahmad Doroudian:<br/></p> <table http://www.streetinsider.com/Press+Releases/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html Tue, 16 Jul 2024 18:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Globe+Newswire/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html <p align="justify">VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- As a result of a review by the British Columbia Securities Commission, BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pvkcJkvvtpynv9wu8j0ZVeV5fBPK3L0voY2mW9JAMeEfacbVS7PB_18STvUMOcu7znklduQKexKWoawI8WH2SRezVUfrzMSxlrXv6CKIdIb919_4gZDFMIaN9Ba8bTY7" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Knpg4KGB_ZvotlFKdqE3VVqEiZ7Izfw2zv6Nxc5pMnUegF-_v6O5fGaBiPTcQEjmfW7bF-nUsM_4TWeaNa3Z9MqBykb-WKZinsZR11U2BW0=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=c5DB9103egOEZr4RJB67HIK7ENijMcYuYSNHXiJX9nc14NORfOdErGTOKX9UfR1ErB7FO5xk2wR1zFLqtouRixctTaMBYEWmwy8Bx5gWGNC8n8iGUi6YLSOTHKeBZfuc" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), is issuing the following press release to clarify disclosures in its past Management Information Circulars (“MIC”) as it relates to beneficial ownership by its Chief Executive Officer, Dr. Ahmad Doroudian:<br/></p> <table http://www.streetinsider.com/Globe+Newswire/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html Tue, 16 Jul 2024 18:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Globe+Newswire/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html <p align="justify">VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- As a result of a review by the British Columbia Securities Commission, BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pvkcJkvvtpynv9wu8j0ZVeV5fBPK3L0voY2mW9JAMeEfacbVS7PB_18STvUMOcu7znklduQKexKWoawI8WH2SRezVUfrzMSxlrXv6CKIdIb919_4gZDFMIaN9Ba8bTY7" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Knpg4KGB_ZvotlFKdqE3VVqEiZ7Izfw2zv6Nxc5pMnUegF-_v6O5fGaBiPTcQEjmfW7bF-nUsM_4TWeaNa3Z9MqBykb-WKZinsZR11U2BW0=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=c5DB9103egOEZr4RJB67HIK7ENijMcYuYSNHXiJX9nc14NORfOdErGTOKX9UfR1ErB7FO5xk2wR1zFLqtouRixctTaMBYEWmwy8Bx5gWGNC8n8iGUi6YLSOTHKeBZfuc" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), is issuing the following press release to clarify disclosures in its past Management Information Circulars (“MIC”) as it relates to beneficial ownership by its Chief Executive Officer, Dr. Ahmad Doroudian:<br/></p> <table http://www.streetinsider.com/Globe+Newswire/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html Tue, 16 Jul 2024 18:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Globe+Newswire/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html <p align="justify">VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- As a result of a review by the British Columbia Securities Commission, BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pvkcJkvvtpynv9wu8j0ZVeV5fBPK3L0voY2mW9JAMeEfacbVS7PB_18STvUMOcu7znklduQKexKWoawI8WH2SRezVUfrzMSxlrXv6CKIdIb919_4gZDFMIaN9Ba8bTY7" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Knpg4KGB_ZvotlFKdqE3VVqEiZ7Izfw2zv6Nxc5pMnUegF-_v6O5fGaBiPTcQEjmfW7bF-nUsM_4TWeaNa3Z9MqBykb-WKZinsZR11U2BW0=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=c5DB9103egOEZr4RJB67HIK7ENijMcYuYSNHXiJX9nc14NORfOdErGTOKX9UfR1ErB7FO5xk2wR1zFLqtouRixctTaMBYEWmwy8Bx5gWGNC8n8iGUi6YLSOTHKeBZfuc" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), is issuing the following press release to clarify disclosures in its past Management Information Circulars (“MIC”) as it relates to beneficial ownership by its Chief Executive Officer, Dr. Ahmad Doroudian:<br/></p> <table http://www.streetinsider.com/Globe+Newswire/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html Tue, 16 Jul 2024 18:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Globe+Newswire/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html <p align="justify">VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- As a result of a review by the British Columbia Securities Commission, BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pvkcJkvvtpynv9wu8j0ZVeV5fBPK3L0voY2mW9JAMeEfacbVS7PB_18STvUMOcu7znklduQKexKWoawI8WH2SRezVUfrzMSxlrXv6CKIdIb919_4gZDFMIaN9Ba8bTY7" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Knpg4KGB_ZvotlFKdqE3VVqEiZ7Izfw2zv6Nxc5pMnUegF-_v6O5fGaBiPTcQEjmfW7bF-nUsM_4TWeaNa3Z9MqBykb-WKZinsZR11U2BW0=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=c5DB9103egOEZr4RJB67HIK7ENijMcYuYSNHXiJX9nc14NORfOdErGTOKX9UfR1ErB7FO5xk2wR1zFLqtouRixctTaMBYEWmwy8Bx5gWGNC8n8iGUi6YLSOTHKeBZfuc" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), is issuing the following press release to clarify disclosures in its past Management Information Circulars (“MIC”) as it relates to beneficial ownership by its Chief Executive Officer, Dr. Ahmad Doroudian:<br/></p> <table http://www.streetinsider.com/Globe+Newswire/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html Tue, 16 Jul 2024 18:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Press+Releases/BetterLife+Announces+Closing+of+a+Private+Placement/23429858.html <p align="justify">VANCOUVER, British Columbia, July 02, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=iEI0DODYp65Nm5vXX4m7IKIKBpAVxIiYR51IopoPeyfydqkDksgQccOslVoFKYOpnpHBiK5Ps-jm6Cq38JXAsykVsqYYabCOsh5D0xUVGbFjWjzSbry-WXVmp-C4luDx" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gOrUxUV07EAV9S64f3rYbX13nSCNrkkwFPr1QA42nrStZTw3VM57k07ZegJW7-pRqsocL0TkDlc8xBYkD5bmCeZhcsuJUu49aCzksYCIPF0=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=707JCUZisdwLrNjaodKOn956SdDdd6bgGpAACHkgk2D_aDVIdyO6YFDnN4BBN6NWww0x7Tt0DBfvL_npQ6YKHyznem53WVCqGCOkeL5HRB6vnP4ACU5k2U_W0x45Z28u" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, announced that it has closed a non-brokered private placement, previously announced on June 13, 2024, pursuant to which the Company issued 1,750,000 units (“Units”) at a price of $0.10 per Unit for aggregate gross proceeds of $175,000 (the “Offering”). Each Unit is comprised of one common http://www.streetinsider.com/Press+Releases/BetterLife+Announces+Closing+of+a+Private+Placement/23429858.html Tue, 02 Jul 2024 18:00:00 -0500 BETR BETRF NPAU O.08486314